Drug Type Trispecific antibody |
Synonyms SIM 0616, SIM0616 |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), PSMA inhibitors(Prostate-specific membrane antigen inhibitors), STEAP1 inhibitors(Six-transmembrane epithelial antigen of the prostate 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Solid tumor | Preclinical | China | 09 Jan 2026 |






